N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 2 N=35 Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
Phase 2 N=29 Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Phase 2 N=83 Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis
Primary: Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE…
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39
N/A N=19 Supplemental Oxygen in Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Change in University of California San Diego Shortness of Breath Questionnaire From Immediately Prior to One Month After Starting Daily-use Supplemental Oxygen — 0.9…
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
Phase 3 N=551 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. — -207.32; -113.59 mL/year — p=0.0002
Phase 3 N=515 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -239.91; -114.65 mL/year — p=<0.0001
Phase 3 N=555 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52 — 16.5; 31.8; 22.7; 9.7 percentage of patients
Phase 3 N=344 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC
Phase 2 N=432 Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Rate of Decline in FVC — -0.190; -0.174; -0.210; -0.162 Liters/year — p=0.8530
N/A N=204 OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Idiopathic Pulmonary Fibrosis
Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters
N/A N=209 IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With IPF Symptoms — 88.0; 51.8; 49.4; 42.9 Percentage of participants
Phase 3 N=435 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC
Phase 2 N=253 A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Lung Diseases, Interstitial
Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777
Phase 3 N=663 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity - Overall Population — -80.82; -187.78 Milliliter per year — p=<.0001
Phase 2 N=147 A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks — -77.70; 2.72; -95.62; 6.10 Milliliter
Phase 3 N=1,177 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 — -183.48; -138.60; -114.65 Milliliters (mL) — p=0.0222
Phase 2 N=120 Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Part A - Number of Participants With Treatment-Emergent Adverse Events — 1 Participants
Phase 2 N=58 Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Serum MMP7 Level — -0.15; 0.88 ng/ml — p=0.2072
N/A N=20 Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis
Precancerous Condition
Primary: Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year — 7; 5; 5 Participants
N/A N=53 A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
Pulmonary Fibrosis
Primary: Cough Count Per Hour (CC/hr) Measured Over a 24-hour Period at Baseline Visit, Week 4, Week 8, and at Day 82 — 10.79; 12.63; 10.36; 12.45 Cough count per hour
Phase 2 N=327 Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 — -5.81; -5.24; -6.31 percent predicted FVC — p== 0.6339
N/A N=34,960 Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
Lung Diseases, Interstitial
Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
Phase 3 N=81 A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) — -191.89; -85.32 Milliliter/year
N/A N=7 Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective — 3; 1; 1; 4 Participants